Menu
No results found.
CINPHA
Cinclus Pharma Holding AB (publ) – STO
Weekly Share Price & Valuation Overview
Market Overview
Open
17.2800
Close
16.8800
High
17.7000
Low
16.8000
Trend
0.30560
Cinclus Pharma Holding AB (publ)
Sweden
• STO - Nasdaq Stockholm
• CINPHA
• Currency: SEK
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.
Key strengths
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
Potential weaknesses
- Negative free cash flow — operations may rely on external financing.
Scale & Structure
Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares.
- Market Cap Total equity value of the company (share price × shares outstanding).
- SEK 752.05M
- Enterprise Value Operating value: market cap + total debt − cash.
- SEK 228.53M
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- SEK 4.58M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- SEK 0.11
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -3.54
- Shares Outstanding
- 46.54M
- Float Shares
- 30.62M
- Implied Shares Outstanding
- 46.54M
Profitability & Efficiency
TTM basis. “Reconciled” = numerator ÷ TTM revenue. EBITDA suppressed where implausible vs revenue.
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-39.34%
- Gross Margin (TTM) Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
100.00%
- ROA Return on assets: net income ÷ total assets.
-
-36.72%
- ROE Return on equity: net income ÷ shareholder equity.
-
-83.22%
Growth
Growth rates are YoY unless labeled QoQ.
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
22.95%
Liquidity & Solvency
Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 12.04
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.07
- Total Cash Cash and equivalents.
- SEK 523.90M
- Total Debt Short + long-term interest-bearing debt.
- SEK 383.00K
- Net Debt Net Cash Total debt − cash (negative = net cash).
- SEK -523.52M
Sharemaestro House View
Confidence: 1
Sharemaestro internal conviction (0–3, higher is better).
Risk: 3
Sharemaestro internal risk profile (0–3, higher is safer).
Operational: 1
Operational quality/consistency (0–3, higher is better).
Composite Score: 1
Overall internal composite (0–3, higher is better).
Suggested Allocation: 1.67%
Indicative portfolio weighting suggestion based on house view.
Structural Insights
(experimental)
Ownership & Liquidity
Free Float
Proportion of shares available for public trading.
65.8%
Insiders
Shares held by company insiders (officers, directors).
37.2%
Institutions
Shares held by institutions (funds, pensions).
35.3%
Capital Structure
Potential Dilution
Increase in share count if options/convertibles exercise.
None detected
Net Debt
Total debt − cash (negative = net cash).
SEK -523.52M
-11430.5% of revenue
Net debt relative to revenue — debt load vs business scale.
Resilience Score
0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating.
100
Methodology Notes
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
As of: 2025-08-18 10:12
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.
AI generated insights not available yet. Sign in to generate the snapshot.